相关实验视频
Updated: Jul 6, 2026

03:37
Self-Administration of Drugs in Mouse Models of Feeding and Obesity
Published on: June 8, 2021
4.5K
评论文章: 肥胖的药理管理 - - 关于已批准的药物,适应症和风险的最新信息
Camille Lupianez-Merly1, Saam Dilmaghani1, Kia Vosoughi1
1Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Alimentary pharmacology & therapeutics
|January 3, 2024
概括
药理学的进步为持续减肥提供了有效的抗肥胖药物 (AOM). 未来的疗法,包括双重和三重的基基,有望在管理肥胖和相关的代谢疾病方面取得进一步的进展.
科学领域:
- 内分泌学和新陈代谢学
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
背景情况:
- 肥胖影响了超过40%的美国人口,构成了重大的公共卫生挑战.
- 虽然生活方式的改变是主要的,但对肥胖的药物干预正在迅速发展.
研究的目的:
- 审查肥胖和体重增加的神经激素基础.
- 评估当前和即将推出的抗肥胖药物 (AOM),包括它们的开发,有效性和风险.
主要方法:
- 在PubMed上进行了全面的文献搜索,使用与肥胖病理生理学,隐形素和减肥相关的术语.
- 分析了FDA批准的AOMs和新兴治疗方法 (如蒂尔泽帕提德和雷塔图提德) 的临床试验数据.
主要成果:
- 该综述涵盖了肥胖的病理生理学,突出强调了因克雷丁和葡萄糖的作用.
- 临床数据证明了AOMs对减肥的有效性,并讨论了代谢益处和不良影响.
- 潜在的风险,如胃肠机动性和吸收变化,也得到了解决.
结论:
- 抗肥胖药物 (AOMs) 在长期体重管理中已被证明是有效的.
- 新兴的治疗方法,包括双重和三重基因克列疗法,预计将扩大对抗肥胖和相关代谢疾病 (如脂肪肝疾病) 的选择.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

